SCHEMBL4608397

SCHEMBL4608397

COC(=O)Cc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
GAA P10253 2/20 0.49
ALDH1A1 P00352 3/20 0.49
TP53 P04637 1/20 0.49
HSD17B10 Q99714 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
TSHR P16473 2/20 0.44
CASP1 P29466 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
ACLY P53396 1/20 0.43
LMNA P02545 1/20 0.43
MYC P01106 1/20 0.43
NR4A1 P22736 1/20 0.43
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15766352 0.87 ABL1 (0.53) KDM4EALDH1A1MEN1KMT2AACLY
SCHEMBL2334848 0.84 ALDH1A1 (0.46) KDM4EALDH1A1TP53HSD17B10CA1
SCHEMBL27560436 0.82 CA1 (0.43) KDM4EALDH1A1CA1CA2MEN1
SCHEMBL11772311 0.81 ALDH1A1 (0.53) KDM4EGAAALDH1A1TP53HSD17B10
SCHEMBL837451 0.81 ALDH1A1 (0.56) KDM4EGAAALDH1A1TP53MEN1
SCHEMBL2334381 0.81 ALDH1A1 (0.57) KDM4EGAAALDH1A1TP53HSD17B10
SCHEMBL7333692 0.81 ALDH1A1 (0.50) KDM4EGAAALDH1A1HSD17B10MEN1
SCHEMBL1525623 0.80 ALDH1A1 (0.54) KDM4EGAAALDH1A1TP53MEN1
SCHEMBL10923842 0.80 ALDH1A1 (0.50) KDM4EALDH1A1TP53MEN1KMT2A
SCHEMBL20521859 0.80 MEN1 (0.47) KDM4EGAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255150-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-10-16 US disclosed
EP-1948630-A2 NOVEL COMPOUNDS AstraZeneca AB (SE) 2008-07-30 EP disclosed
WO-2007052023-A2 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255150-A1 Novel Compounds CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 KDM4E 3205/4885GAA 97/4885ALDH1A1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.